How technology is reshaping cognitive assessment: Lessons from the Framingham Heart Study.
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This article elucidates how the Boston process approach (BPA) can amplify the role of neuropsychology in the study of preclinical and clinical dementia, particularly Alzheimer's disease (AD), and how advancements in technology expand BPA capacity objectively and exponentially. METHOD: The BPA is based on a conceptualization of cognition as being comprised of multiple processes, the nature of which could not possibly be captured by a single score on a test or battery of tests. Identification of these processes is only possible with careful observation of an individual during the entire testing process to determine how, when, and why a person fails, which helps to reveal the integrity of the cognitive processes underlying the behavior. RESULTS: BPA use within the Framingham Heart Study is described, including how digital technology has been incorporated to enhance the sensitivity of BPA to detect insidious onset changes even earlier than had been previously possible. The digital technology movement will dramatically alter the means by which cognitive function is assessed going forward. CONCLUSIONS: Technological advances will catalyze groundbreaking discoveries for effective treatments of neurodegenerative cognitive disorders, such as AD, and inform novel strategies for dementia prevention and sustained lifelong cognitive health. (PsycINFO Database Record
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Podsakoff, P. M., MacKenzie, S. B., Lee, J.-Y., & Podsakoff, N. P. (2003) · Journal of Applied Psychology · doi:10.1037/0021-9010.88.5.879 · Cited by 82,194
Mastering the game of Go with deep neural networks and tree search
Silver, D., Huang, A., Maddison, C. J., Guez, A., Sifre, L., van den Driessche, G., Schrittwieser, J., Antonoglou, I., Panneershelvam, V., Lanctot, M., et al. (2016) · Nature · doi:10.1038/nature16961 · Cited by 15,612
Predicting the future - big data, machine learning, and clinical medicine
Obermeyer, Z., & Emanuel, E. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1606181 · Cited by 3,652
Grant, D. A., & Berg, E. (1948) · Journal of Experimental Psychology · doi:10.1037/h0059831 · Cited by 2,244
Wechsler Adult Intelligence Scale--Fourth Edition
Wechsler, D. (2012) · PsycTESTS Dataset · doi:10.1037/t15169-000 · Cited by 2,232
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Further, the continued failure of clinical trial studies reflects, in part, treatment interventions that are too late to reverse course of the disease (Sperling, Karlawish, & Johnson, 2013; Salloway et al., 2014; Doody et al., 2014; Belluck, 2016; Taylor, 2017).”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“Further, the continued failure of clinical trial studies reflects, in part, treatment interventions that are too late to reverse course of the disease (Sperling, Karlawish, & Johnson, 2013; Salloway et al., 2014; Doody et al., 2014; Belluck, 2016; Taylor, 2017).”
BackgroundTroyer, A. K., Moscovitch, M., & Winocur, G. (1997) · Neuropsychology · doi:10.1037/0894-4105.11.1.138 · Cited by 1,241
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Incidence of dementia over three decades in the Framingham heart study
Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504327 · Cited by 1,051
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Splansky, G. L., Corey, D., Yang, Q., Atwood, L. D., Cupples, L. A., Benjamin, E. J., D'Agostino, R. B., Fox, C. S., Larson, M. G., Murabito, J. M., et al. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm021 · Cited by 860
The Preclinical Phase of Alzheimer Disease: A 22-Year Prospective Study of the Framingham Cohort
Elias, M. F., Beiser, A., Wolf, P. A., Au, R., White, R. F., & D'Agostino, R. B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.808 · Cited by 716 · cited 3×
“Linn et al. (1995) and Elias et al. (2000) suffered from important methodological limitations that did not meet contemporary standards, such as the exclusion of AD cases of mild severity and people with low education.”
BackgroundSelf-citationReiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541 · cited 1×
“However, more recent research also suggests that the earliest indicators of AD may predate clinical onset by as much as two decades (Reiman et al., 2012), which would mean that these markers are not restricted to the oldest decades of life.”
BackgroundPrevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R., Knoefel, J. E., CobbS, J., Belanger, A., D'Agostino, R. B., & White, L. R. (1992) · Neurology · doi:10.1212/wnl.42.1.115 · Cited by 527
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R. T., Knoefel, J. E., Cobb, J. L., Belanger, A. J., White, L. R., & D'Agostino, R. B. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.515 · Cited by 470
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291
Forbes-McKay, K. E., & Venneri, A. (2005) · Neurological Sciences · doi:10.1007/s10072-005-0467-9 · Cited by 261 · cited 1×
“…2015), the quality of verbal expression (Mueller et al., 2016; Wetter et al., 2006; Cuentos, Arango-Lasprilla, Uribe, Valencia, & Lopera, 2007; Forbes-McKay & Venneri, 2005), intrusion errors (Libon, Bondi et al., 2011), proactive interference (Loewenstein et al., 2004; Loewenstein et al.,…”
BackgroundAmyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study
Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188 · cited 2×
“…studies of MCI cases, however, revealed that hallmark AD tau and amyloid pathology were already present in medial temporal and cortical regions of the brain (Forsberg et al., 2008; Jack et al., 2008; Jack et al., 2009; Koivunen et al., 2011; Okello et al., 2009; Mufson et al., 2012).”
BackgroundPerrotin, A., La Joie, R., de La Sayette, V., Barré, L., Mézenge, F., Mutlu, J., Guilloteau, D., Egret, S., Eustache, F., & Chételat, G. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.011 · Cited by 179
Snitz, B. E., Weissfeld, L. A., Cohen, A. D., Lopez, O. L., Nebes, R. D., Aizenstein, H. J., McDade, E., Price, J. C., Mathis, C. A., & Klunk, W. E. (2015) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.01.008 · Cited by 140 · cited 1×
“While cognitive complaints serve as a surrogate preclinical measure of decline (Buckley et al., 2015; Snitz et al., 2015; Perrotin et al., 2017; La Joie et al., 2016), they are subject to the inherent bias of self-report (Podsakoff, MacKenzie, Lee, & Podsakoff, 2003; van de Mortel, 2008).”
BackgroundLinguistic changes in verbal expression: A preclinical marker of Alzheimer's disease
CUETOS, F., ARANGO-LASPRILLA, J. C., URIBE, C., VALENCIA, C., & LOPERA, F. (2007) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617707070609 · Cited by 102
Seshadri, S., Beiser, A., Au, R., Wolf, P. A., Evans, D. A., Wilson, R. S., Petersen, R. C., Knopman, D. S., Rocca, W. A., Kawas, C. H., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.002 · Cited by 97
Self-citation
Cited by
Amini, S., Hao, B., Zhang, L., Song, M., Gupta, A., Karjadi, C., Kolachalama, V. B., Au, R., & Paschalidis, I. C. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12721 · Cited by 76
Self-citationSpeech patterns during memory recall relates to early tau burden across adulthood
Young, C. B., Smith, V., Karjadi, C., Grogan, S., Ang, T. F. A., Insel, P. S., Henderson, V. W., Sumner, M., Poston, K. L., Au, R., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13731 · Cited by 27
Self-citationYuan, J., Au, R., Karjadi, C., Ang, T. F., Devine, S., Auerbach, S., DeCarli, C., Libon, D. J., Mez, J., & Lin, H. (2022) · Journal of Medical Internet Research · doi:10.2196/34513 · Cited by 22
“The detailed cognitive ascertainment procedure and quality control in the FHS have been described previously [37,38].”
MethodSelf-citation
Metadata
- Authors
- Au, R., Piers, R. J., & Devine, S.
- Venue
- Neuropsychology
- Published
- 2017-11
- Volume
- 31
- Issue
- 8
- Pages
- 846-861
- ISSN
- 0894-4105 (ISSN-L)
- 1931-1559
- OpenAlex
- W2785746589
- Cited by
- 49
- References
- 24
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.